Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00415909 · ClinicalTrials.gov registry record · Phase 2
TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00415909: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00415909 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00415909, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Objectives: * To determine the response rate and duration of response with combination of TALL-104 cells and imatinib mesylate (IM) therapy in patients with chronic myelogenous leukemia in chronic phase, that have not achieved, or have lost, adequate response to IM. * To determine the toxicity of the combination of TALL-104 cells and IM therapy in this patient population.
Primary Outcome
Rate is defined as number of participants with response of Major and Complete cytogenetic response out of total study participants. Response evaluated at one and 3 months from start of therapy, then every 3 months in patients with response, for one year, then every 6-12 months. Responses classified according to suppression of Philadelphia (Ph) chromosome by cytogenetic analysis: a) Complete cytogenetic response - Not Ph positive; b) Major cytogenetic response - Ph positive 1-34% of pretreatment
Interventions
- DRUG Imatinib Mesylate (IM)
- DRUG TALL-104 cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2006-12 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Why NCT00415909 stopped before completion
NCT00415909 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Imatinib Mesylate (IM) is the first listed.
NCT00415909 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00415909 about?
NCT00415909 is a clinical study titled "TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients". Objectives: * To determine the response rate and duration of response with combination of TALL-104 cells and imatinib mesylate (IM) therapy in patients with chronic myelogenous leukemia in chronic phase, that have not achieved, or have lost, adequate response to IM. * To determine the toxicity of t...
What is the current status of trial NCT00415909?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2006-12. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00415909?
The interventions under investigation include: Imatinib Mesylate (IM) (DRUG), TALL-104 cells (DRUG).
Who is sponsoring clinical trial NCT00415909?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00415909's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia